• JAYAN PARIYANI SAVARINGAL Department of Pharmacology, Government Medical College, Kozhikode, Kerala, India.
  • SHILPA K ADR Monitoring Center, Department of Pharmacology, Government Medical College, Kozhikode, Kerala, India.
  • NOUFIRA P Department of Pharmacology, Government Medical College, Kozhikode, Kerala, India.
  • ABDUL GAFOOR Department of Neurology, Government Medical College, Kozhikode, Kerala, India.



Guillain Barre Syndrome (GBS), Adverse Events Following Immunization, Covishield Vaccine, COVID-19


Guillain barre syndrome (GBS) is a rare but fatal autoimmune disease affecting the nervous system. The occurrence of GBS after COVID vaccination is rare and its exact cause is still unknown. Hence, here, we are trying to describe the pattern of GBS following the first dose of COVID-19 vaccination as a case series. The retrospective case series study was carried out by analyzing the serious AEFI (Adverse Events Following Immunization) case notification form reported by health-care professionals to ADR Monitoring Center during the period of March 2021–September 2021.The purpose of these case reports is to ensure proper surveillance methods to monitor the safety of COVID vaccination and to promote further researches which is required to determine the possible link between GBS and COVID-19 vaccination.


Download data is not yet available.


Nguyen TP, Taylor RS. Guillain Barre Syndrome. Treasure Island: StatPearls; 2022.

Mer RJ, Kakasaniya GG, Acharya TA, Mehta DS. A participant centred surveillance of adverse events following coronavirus disease immunization phase 1 at a tertiary care teaching hospital. Natl J Physiol Pharm Pharmacol 2022;12:312-6.

India-COVID19 Vaccine Tracker. Available from: https://covid19. [Last accessed on 2021 Nov 11].

Voysey M, Clemens SA, Madhi SA, Weckx LY, Folegatti PM, Aley PK, et al. Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: An interim analysis of four randomized controlled trials in Brazil, South Africa, and the UK. Lancet 2021;397:99-111. doi: 10.1016/S0140-6736(20)32661-1, PMID 33306989.

Patel SU, Khurram R, Lakhani A, Quirk B. Guillain-Barre syndrome following the first dose of the chimpanzee adenovirus-vectored COVID-19 vaccine, ChAdOx1. BMJ Case Rep 2021;14:e242956.

Neustadt RE, Fineberg HV. The Swine Flu Affair: Decision-Making on a Slippery Disease. Washington, DC: National Academies Press; 1978.

Perez-Vilar S, Hu M, Weintraub E, Arya D, Lufkin B, Myers T, et al. Season. J Infect Dis 2020;223:416-25.

Zhao H, Shen D, Zhou H, Liu J, Chen S. Guillain-Barré syndrome associated with SARS-CoV-2 infection: Causality or coincidence? Lancet Neuro 2020;19:383-4. doi: 10.1016/S1474-4422(20)30109-5, PMID 32246917

Chandler RE. Optimizing safety surveillance for COVID-19 vaccines. Nat Rev Immunol 2020;20:451-2. doi: 10.1038/s41577-020-0372-8, PMID 32555401.

Zuberbühler P, Conti ME, León-Cejas L, Maximiliano-González F, Bonardo P, Miquelini A, et al. Guillain-Barre syndrome associated to COVID-19 infection: A review of published case reports. Rev Neurol 2021;72:203-12. doi: 10.33588/rn.7206.2020487, PMID 33710610

James J, Jose J, Gafoor VA, Smita B, Balaram N. Guillain-Barré syndrome following ChAdOx1 nCoV-19 COVID-19 vaccination: A case series. Neurol Clin Neurosci 2021;9:402-5. doi: 10.1111/ ncn3.12537, PMID 34548920

Min YG, Ju W, Ha YE, Ban JJ, Lee SA, Sung JJ, et al. Sensory guillain-barre syndrome following the ChAdOx1 nCov-19 vaccine: Report of two cases and review of literature. J Neuroimmunol 2021;359:577691. doi: 10.1016/j.jneuroim.2021.577691, PMID 34416410

López-Hernández J, Lisette BR, Adib Jde S, Eunice MJ, Elizabeth LM, Erika GL, et al. Guillain-Barré syndrome following SARS-CoV-2 vaccination: Is there a real association? Neuroimmunol Rep 2022;2:100050.

Introna A, Caputo F, Santoro C, Guerra T, Ucci M, Mezzapesa DM, et al. Guillain-Barré syndrome after AstraZeneca COVID-19- vaccination: A causal or casual association? Clin Neurol Neurosurg 2021;208:106887. doi: 10.1016/j.clineuro.2021.106887, PMID 34418708

Swan DA, Bracis C, Janes H, Moore M, Matrajt L, Reeves DB, et al. COVID-19 vaccines that reduce symptoms but do not block infection need higher coverage and faster rollout to achieve population impact. Sci Rep 2021;11:15531. doi: 10.1038/s41598-021-94719-y, PMID 34330945



How to Cite

SAVARINGAL, J. P., S. K, N. P, and A. GAFOOR. “ KOZHIKODE: A CASE SERIES”. Asian Journal of Pharmaceutical and Clinical Research, vol. 15, no. 7, July 2022, pp. 3-5, doi:10.22159/ajpcr.2022.v15i7.44821.



Case Study(s)